DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.
Other equities analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, DiaMedica Therapeutics has an average rating of “Hold” and a consensus target price of $12.00.
View Our Latest Research Report on DiaMedica Therapeutics
DiaMedica Therapeutics Stock Performance
NASDAQ:DMAC opened at $8.79 on Friday. DiaMedica Therapeutics has a 1 year low of $5.24 and a 1 year high of $11.00. The firm has a 50 day moving average of $8.21 and a 200-day moving average of $7.20. The stock has a market capitalization of $474.04 million, a P/E ratio of -11.57 and a beta of 0.95.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). As a group, analysts forecast that DiaMedica Therapeutics will post -0.84 EPS for the current fiscal year.
Hedge Funds Weigh In On DiaMedica Therapeutics
A number of institutional investors have recently modified their holdings of the stock. AWM Investment Company Inc. acquired a new position in shares of DiaMedica Therapeutics during the second quarter worth approximately $253,000. Tocqueville Asset Management L.P. acquired a new stake in shares of DiaMedica Therapeutics in the third quarter valued at approximately $332,000. Bank of America Corp DE increased its holdings in shares of DiaMedica Therapeutics by 62.5% in the first quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after purchasing an additional 16,446 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of DiaMedica Therapeutics in the first quarter valued at approximately $356,000. Finally, Sei Investments Co. raised its position in DiaMedica Therapeutics by 100.0% in the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock worth $754,000 after purchasing an additional 55,660 shares during the last quarter. 10.12% of the stock is owned by institutional investors.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.
Further Reading
- Five stocks we like better than DiaMedica Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
